Malignant brain tumor affects a large number of patients and often have poor prognosis and low response to therapeutics. An indicator of the progress of brain tumor and its response to treatment is the DNA repair protein, O6-methylguanine-DNA methyltransferase (MGMT). As such, accurate assessment of MGMT is of great clinical significance. Biospy is not only invasive but also has the risk of undersampling the tumorous tissue. We presented a novel deep learning model that uses multi-MRI modalities to assess the expression of MGMT in glioblastoma (GBM) patients. Results showed that the model can achieve good performance.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords